Monday, January 18, 2021
Home Latest Pharma-News US Food and Drug Administration (FDA) approved Calquence (acalabrutinib) for adult patients...

US Food and Drug Administration (FDA) approved Calquence (acalabrutinib) for adult patients with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL)

Nov 21,2019: AstraZeneca announced that the US Food and Drug Administration (FDA) has approved Calquence (acalabrutinib) for adult patients with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL).

This approval is based on positive reports from the interim analyses of two Phase III clinical trials, ELEVATE-TN in patients with previously untreated CLL and ASCEND in patients with relapsed or refractory CLL.

- Advertisement -

Calquence in combination with obinutuzumab or as a monotherapy significantly reduced the relative risk of disease development or death versus the comparator arms in both 1st-line and relapsed or refractory CLL.

Results from both trials shows that safety and tolerability of Calquence were consistent with its established profile.

This approval of Calquence provides new hope for patients with one of the most common types of adult leukaemia, offering incomparable efficacy and a constructive tolerability profile.

In the Calquence combination arm, risk of disease progression or death was reduced by 90%and in the monotherapy arm it was reduced by 80%. https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2019/calquence-approved-in-the-us-for-adult-patients-with-chronic-lymphocytic-leukaemia-21112019.html

LEAVE A REPLY

Please enter your comment!
Please enter your name here

four + one =

Most Popular

GSK presents positive efficacy data of dostarlimab at ASCO Gastrointestinal Cancers Symposium

January 16, 2021: "GlaxoSmithKline (GSK) plc announced updated data from GARNET cohort F evaluating dostarlimab in mismatch repair-deficient (dMMR) non-endometrial advanced solid...

Bharat Biotech signs agreement with Precisa Medicamentos for supply of ‘COVAXIN™’ to Brazil

January 12, 2020: "Bharat Biotech announced that it has signed an agreement with Precisa Medicamentos for the supplies of COVAXIN™ to Brazil.

What Is a Blockbuster Drug?

What Is a Blockbuster Drug? "Blockbuster drugs are those that generate at least $1 billion of revenue per...

Boehringer Ingelheim and Enara Bio join forces to discover Cancer Immunotherapies

January 12th, 2021: Boehringer Ingelheim and Enara Bio announced that they have entered into a strategic collaboration and licensing agreement to research...